News
Public · Published
Rosenblatt downgrades Adtran Holdings to Neutral from Buy, lowers price target to $6.25 from $15
Rosenblatt downgraded Adtran Holdings from Buy to Neutral and cut its price target to $6.25 from $15, a 58.3% decrease. The revised target implies 23.5% upside from the November 3 closing price of $5.06.
Published:
Updated:
What happened
Rosenblatt downgraded Adtran Holdings from Buy to Neutral and cut its price target to $6.25 from $15, a 58.3% decrease. The revised target implies 23.5% upside from the November 3 closing price of $5.06.
Confirmed
Global impact / market context
The downgrade signals that Rosenblatt has become less positive about Adtran’s shares, while its lower target suggests a reduced estimate of their potential value. Investors may reassess expectations, which can influence demand for the stock, but the article gives no reason for the change.
Analyst inference
The new $6.25 target remains above the cited November 3 close of $5.06, so Rosenblatt still sees potential upside despite moving its rating from Buy to Neutral. The article provides no company results, business outlook, or broader market information to explain the revised view.
Analyst inference
What to watch
- Check for any later Rosenblatt rating or target changes; these would show whether the shift to Neutral reflects a lasting reassessment or a temporary adjustment. Analyst inference
- Look for company updates on sales, costs, or cash available, which could clarify whether changes in Adtran’s business outlook help explain the lower target. Analyst inference
- Compare the share price with the revised $6.25 target and the cited $5.06 November 3 close; the article reports the target’s implied upside as 23.5%. Confirmed
Evidence
- Original source link unavailable